| 别名 | GSK1325756 (Danirixin) 达尼利辛 |
| 产品名 | Danirixin |
| CAS号 | 954126-98-8 |
| 化学式 | C₁₉H₂₁ClFN₃O₄S |
| 分子量 | 441.9 |
| 溶解度 | DMSO : 8 mg/mL (18.10 mM) |
| 靶点 | Danirixin is a selective, and reversible CXCR2 antagonist, with IC50 of 12.5 nM for CXCL8. |
| 储存条件 | Store at -20°C |
| 用途 | 仅供科学研究使用!不能用于人体及动物治疗 |
| 纯度 | >99% |
靶点及简介 :Danirixin is a selective, and reversible CXCR2 antagonist, with IC50 of 12.5 nM for CXCL8.
一种高亲和力的选择性CXCR2拮抗剂,抑制CXCL8 (IL-8)结合的IC50值为12.5 nM。
| 分子量 | 441.90 | ||
|---|---|---|---|
| 化学式 | C19H21ClFN3O4S | ||
| CAS号 | 954126-98-8 | ||
| 储存条件 (自收到货起) | 3年 | -20°C | 粉状 |
| 1年 | -80°C | 溶于溶剂 | |
GSK1325756 (Danirixin) is a non-peptide, high affinity, selective and reversible CXCR2 antagonist (IC50 for CXCL8 = 12.5 nM). GSK1325756 has demonstrated potent antagonism of CXCR2 activity in vitro and anti-inflammatory effects in various preclinical models. Danirixin (GSK1325756) is used for the treatment of chronic obstructive pulmonary disease (COPD).
验证:
参考文献:
| DMSO | 88 mg/mL (199.14 mM) |
| Water | Insoluble |
| Ethanol | Insoluble |
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2630 mL | 11.3148 mL | 22.6296 mL |
| 5 mM | 0.4526 mL | 2.2630 mL | 4.5259 mL |
| 10 mM | 0.2263 mL | 1.1315 mL | 2.2630 mL |
| 50 mM | 0.0453 mL | 0.2263 mL | 0.4526 mL |